158 related articles for article (PubMed ID: 36877285)
1. Mosunetuzumab (Lunsumio) for follicular lymphoma.
Med Lett Drugs Ther; 2023 Mar; 65(1671):e41-e42. PubMed ID: 36877285
[No Abstract] [Full Text] [Related]
2. Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA.
Lin SW; Shapouri S; Parisé H; Bercaw E; Wu M; Kim E; Matasar M
Pharmacoeconomics; 2024 May; 42(5):569-582. PubMed ID: 38300452
[TBL] [Abstract][Full Text] [Related]
3. Mosunetuzumab: First Approval.
Kang C
Drugs; 2022 Jul; 82(11):1229-1234. PubMed ID: 35947358
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Budde LE; Sehn LH; Matasar M; Schuster SJ; Assouline S; Giri P; Kuruvilla J; Canales M; Dietrich S; Fay K; Ku M; Nastoupil L; Cheah CY; Wei MC; Yin S; Li CC; Huang H; Kwan A; Penuel E; Bartlett NL
Lancet Oncol; 2022 Aug; 23(8):1055-1065. PubMed ID: 35803286
[TBL] [Abstract][Full Text] [Related]
5. Copanlisib (Aliqopa) for relapsed follicular lymphoma.
Med Lett Drugs Ther; 2018 Apr; 60(1545):e74-e75. PubMed ID: 29667951
[No Abstract] [Full Text] [Related]
6. Thinking "outside the germinal center": Re-educating T cells to combat follicular lymphoma.
Kambhampati S; Shouse G; Danilov AV
Blood Rev; 2023 Sep; 61():101099. PubMed ID: 37173225
[TBL] [Abstract][Full Text] [Related]
7. Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting.
Cao Y; Marcucci EC; Budde LE
J Hematol Oncol; 2023 Jun; 16(1):69. PubMed ID: 37381053
[TBL] [Abstract][Full Text] [Related]
8. [Drug approval: Mosunetuzumab - third-line therapy in follicular lymphoma].
Gondran C; Ysebaert L
Bull Cancer; 2022 Nov; 109(11):1105-1106. PubMed ID: 36167561
[No Abstract] [Full Text] [Related]
9. FDA grants accelerated approval of mosunetuzumab for relapsed, refractory follicular lymphoma.
Nierengarten MB
Cancer; 2023 May; 129(10):1465-1466. PubMed ID: 37088993
[No Abstract] [Full Text] [Related]
10. Mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma.
Buske C
Lancet Oncol; 2022 Aug; 23(8):967-969. PubMed ID: 35803285
[No Abstract] [Full Text] [Related]
11. Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma.
Cohen JA; Ghobadi A
Expert Rev Anticancer Ther; 2022 Sep; 22(9):903-914. PubMed ID: 35786133
[TBL] [Abstract][Full Text] [Related]
12. In brief: Lisocabtagene maraleucel (Breyanzi) for large B-cell lymphoma.
Med Lett Drugs Ther; 2023 Jun; 65(1679):e104-e105. PubMed ID: 37339093
[No Abstract] [Full Text] [Related]
13. Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma.
Bosch F; Kuruvilla J; Vassilakopoulos TP; Maio DD; Wei MC; Zumofen MB; Nastoupil LJ
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):105-121. PubMed ID: 37981564
[TBL] [Abstract][Full Text] [Related]
14. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
Proudman D; Nellesen D; Gupta D; Adib D; Yang J; Mamlouk K
Adv Ther; 2022 Apr; 39(4):1678-1696. PubMed ID: 35157216
[TBL] [Abstract][Full Text] [Related]
15. Axicabtagene ciloleucel (Yescarta) for B-cell lymphoma.
Med Lett Drugs Ther; 2018 Jul; 60(1551):e122-e123. PubMed ID: 30036350
[No Abstract] [Full Text] [Related]
16. Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma.
Eltantawy A; Vallejos X; Sebea E; Evans K
Ann Pharmacother; 2019 Sep; 53(9):954-958. PubMed ID: 30813760
[No Abstract] [Full Text] [Related]
17. Copanlisib for the treatment of adults with relapsed follicular lymphoma.
Magagnoli M; Carlo-Stella C; Santoro A
Expert Rev Clin Pharmacol; 2020 Aug; 13(8):813-823. PubMed ID: 32576028
[TBL] [Abstract][Full Text] [Related]
18. [New European approvals: Tisagenlecleucel and Axicabtagene ciloleucel CAR-T cells - Follicular lymphoma after at least two and three prior lines of therapy].
Cordeil S; Bachy E
Bull Cancer; 2022 Nov; 109(11):1106-1108. PubMed ID: 36088178
[No Abstract] [Full Text] [Related]
19. How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?
Huguet M; Raimond V; Kaltenbach E; Augusto V; Perrier L
Bull Cancer; 2021 Dec; 108(12):1170-1180. PubMed ID: 34561025
[TBL] [Abstract][Full Text] [Related]
20. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]